TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06732362

Intervention type: OTHER
Intervention: Different DPN ratings
Description: According to the TCSS grading scale, DPN patients were graded into different grades, and the mild and severe groups and the control group were selected to observe the clinical effects between the three groups

Intervention type: OTHER
Intervention: Different DPN ratings
Description: According to the TCSS grading scale, DPN patients were graded into different grades, and the mild and severe groups and the control group were selected to observe the clinical effects between the three groups

Intervention type: OTHER
Intervention: Different DPN ratings
Description: According to the TCSS grading scale, DPN patients were graded into different grades, and the mild and severe groups and the control group were selected to observe the clinical effects between the three groups
Study: NCT06732648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS8179 injection
Description: HRS8179 injection; high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS8179 injection
Description: HRS8179 injection; high dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HRS8179 blank preparation.
Description: HRS8179 blank preparation.
Study: NCT06732128

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nature-based virtual reality applications and videos
Description: Participants will receive nature-based applications available on the Oculus platform, as well as nature-based 360 videos with the same content as the control group however in a 360 format.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nature-based videos
Description: Participants will receive YouTube links to watch nature-based videos on a device (e.g., a tablet).
Study: NCT05517850

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapist-guided cognitive behavioral therapy administered online
Description: This intervention consists of 10 modules of education and interventions and lasts 12 weeks. An introduction provides information about CBT and AD. Step by step, the participants are introduced to the proposed active treatment components: mindfulness training, and exposure with response prevention. Through this whole process, the participant is guided by a therapist. The therapist may be contacted through a secure internet platform at any time and responds within 48 hours. Participants reads the education material, construct exercises to perform, describes their progress in homework assignments, and receives feedback from their therapist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-guided digital intervention based on cognitive behavioral therapy
Description: Participants will access a digital platform, read information, and perform exercises in their everyday life. The main treatment components are mindfulness and exposure with response prevention, with a specific focus on itch. Participants will be able to practice mindfulness with the help of instructions and examples. Participants will receive detailed instructions and guidance, and get to choose exposure exercises from a long list of examples. Participants will also be free to create their own relevant exposure situations within the intervention. Digital self-care consists of 8 modules. The only active interventions, mindfulness and exposure are introduced week 1 and 2, respectively. From week 3-7, no new interventions are introduced and participants are advised to continue practicing the interventions, but there is a new theme of education each week, to act as inspiration for exercises. The last 4 weeks, the participant is merely advised to continue practice.
Study: NCT06733519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalmefene
Description: Th-104 Nalmefene Mucoadhesive Buccal strip
Study: NCT06354985

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil 200mg
Description: Modafinil 200mg daily for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil 200mg
Description: Modafinil 200mg daily for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo daily for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily for 8 weeks.
Study: NCT06733519

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to TH-104
Study: NCT06354985

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Program One
Description: Exercise Program One three times per week for 8 weeks.
Study: NCT06110702

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMDR
Description: Eye movement Desensitization and Reprocessing (as described in the 8-phases protocol), administered both online or in presence.
Study: NCT06732115

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One-step polishing system with nanohybrid resin composite restorations.
Description: one-step polishing system using OneGloss by Shofu

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multistep system polishing system Super-Snap X-treme (Shofu) with nanohybrid resin composite restorations.
Description: A multi-step polishing system
Study: NCT06732505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [225Ac]Ac-DOTATATE
Description: The dose escalation phase will be divided into two cohorts: patients who had previously received 177Lu-PRRT will be enrolled in cohort 1, and patients who had not received 177Lu-PRRT will be enrolled in cohort 2. Dose escalation was performed independently in the two cohorts. DL1 will be administered as a dose of 90kBq/kg per cycle, and DL2 will be administered as a single dose of 120kBq/kg per cycle.Every patient will receive one \[225Ac\]Ac-DOTATATE infusion every 8 weeks for up to 4 cycles.
Study: NCT06354985

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise Program Two
Description: Exercise Program Two three times per week for 8 weeks.
Study: NCT06732973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS005
Description: JS005：The drug was administered by a single subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JS005
Description: JS005：The drug was administered by a single subcutaneous injection
Study: NCT06732778

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education (PNE)
Description: PNE was planned online for clients 1 week before menstruation in the form of speaking sessions in a presentation format. The training will be conveyed in relation to pain during menstruation. Visual aids, examples and metaphors will be used to improve patient understanding in the training. Ankle sprain picture, speeding bus picture, action potential picture, picture showing membrane resting potential, rusty nail picture, whole body nervous system picture, neuromatrix picture, lion and lion cub picture that helps explain stress responses, curious neighbors picture etc. will be used. The training session is planned to last between 2 and 4 hours.~The distribution of pain neuroscience training topics will be implemented in the order given below, with 10 main headings.~* Pain and the Biopsychosocial Model~* Injury and pain are not equivalent, pain is a brain output rather than an input~* Action potential, normal electrical activity of nerves and conduction~* Biological process of ion chann

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group (CG)
Description: The control group will not receive any training or practice.
Study: NCT06733233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DXd combined with immune checkpoint inhibitor
Description: Subjects who are eligible for the study and have signed informed consent will receive T-DXd in combination with an immune checkpoint inhibitor. The specific dosing regimen is as follows: T-DXd (5.4 mg/kg i.v. q3w) every 3 weeks for a total of 8 courses. Teraplizumab (240 mg/kg i.v. q3w), 1 course every 3 weeks for a total of 8 courses.
Study: NCT06732700

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Neuromuscular Inhibition Technique and Posture Corrective Exercises.
Description: INIT will be performed for experimental group and then posture corrective exercises will be performed and for control group only posture corrective exercises will be performed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Neuromuscular Inhibition Technique and Posture Corrective Exercises.
Description: INIT will be performed for experimental group and then posture corrective exercises will be performed and for control group only posture corrective exercises will be performed
Study: NCT06733493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: integrated psychosocial care
Description: Employment of a psychologist in psychotherapeutic training as a member of the multiprofessional team at the ICU ward for the duration of one year. Tasks: Psychosocial Support for staff, patients and their relatives.
Study: NCT06733792

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-based intervention
Description: * 1st week: Daily self-report on cannabis and tobacco use, myths regarding cannabis use and its health consequences, motives for cannabis use reduction/quitting, psychoeducation concerning withdrawal symptomatology, therapist's recommendation (progressive reduction of cannabis use).~* 2nd week: Daily self-report on cannabis and tobacco use, myths regarding cannabis use and its health and behavioral consequences, identification of triggers, alternatives to cannabis use, therapist's recommendation (progressive reduction of cannabis use).~* 3rd week: Daily self-report on cannabis and tobacco use benefits from quitting cannabis, behavioral activation, diaphragmatic breathing, training in social abilities, strategies to prevent smoking, therapist's recommendation (progressive reduction of cannabis use).~* 4th week: Daily self-report on cannabis and tobacco use (i.e., nº of joints/cigarettes), high-risk situations for relapse, lapse vs. relapse, coping strategies, relapse prevention plan.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-help guide
Description: Psychoeducation on cannabis.
Study: NCT06733376

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Processing Therapy
Description: Cognitive Processing Therapy is a first-line intervention for the treatment of PTSD that focuses on changing unhelpful patterns of thinking.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy
Description: Cognitive Processing Therapy is a first-line intervention for the treatment of PTSD that focuses on changing unhelpful patterns of thinking.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure
Description: Prolonged Exposure is an evidence-based treatment for PTSD that helps to reduce the intensity of distress by gradually exposing participants to trauma-related memories, feelings, and situations in real life.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Skills Training for Affective and Interpersonal Regulation
Description: Skills Training for Affective and Interpersonal Regulation (STAIR) is a evidence-based treatment geared towards helping regulate emotional and interpersonal needs of those with PTSD.
Study: NCT06750887

Intervention type: OTHER
Intervention: Normal condition
Description: The normal condition IS measured as a lumbar extension without VR until the onset of pain.

Intervention type: OTHER
Intervention: Understated condition
Description: It involves an illusion with virtual reality where the patients perform a lumbar flexion until the onset of pain and they feel a 20% less movement in the VR (understated visual feedback)

Intervention type: OTHER
Intervention: OVERSTATED CONDITION
Description: It involves an illusion with virtual reality where the patients perform a lumbar flexion until the onset of pain and they feel a 20% more movement in the VR (understated visual feedback)
Study: NCT06354985

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Program Two
Description: Exercise Program Two three times per week for 8 weeks.
Study: NCT05572957

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guideline-Directed Medical Therapy(GDMT)
Description: Quadruple anti-heart failure drug therapy: BB, ACEI/ARB/ARNI, MRA, and SGLT2i. If the initial dose according to guidelines is tolerated, the protocol would then direct the uptitration of medication dose over time to a specified target dose, unless not well tolerated.~\*Criteria for \<3 months of optimized (complete) GDMT: 1) according to the latest management of HF, any of the new quadruple therapy is not used if the condition allowed; Or 2) the dose of any drug dose not reach the maximum tolerated target; Or 3) under the maximum tolerated dose of BB, ivabradine is not added with a heart rate still ≥70 bpm at rest.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: left bundle branch pacing combined with Guideline-Directed Medical Therapy(LBBP+GDMT)
Description: GDMT is the same as Drug intervention. LBBP is confirmed when: 1) the LBBB morphology disappeared and the paced RBBB pattern (typical or atypical) is observed in V1; and 2) LVAT is ≤100 ms at low output(≤3 V/0.5 ms); and at least 1 of the following is achieved: a) abrupt shortening of LVAT by \>10 ms during mid/deep septal lead placement with a RBBB pattern in V1 at high output, which then remains short and constant at high and low output with further advancement of the lead to the final position; b) transition from nonselective to selective LBBP (QRS morphology transition from atypical RBBB to typical rsR' pattern in V1 and wide/large S-wave in V6 , with the appearance of an isoelectric segment and no LVAT change at high and low outputs); and c) transition from nonselective LBBP to LV septal pacing (lengthening of LVAT by at least 10 ms with or without obvious QRS morphology transition during threshold testing).~HBP or BiVP is attempted using the standard-of-care technique.
Study: NCT05812235

Intervention type: PROCEDURE
Intervention: esophagectomy
Description: esophagectomy
Study: NCT03037814

Intervention type: DEVICE
Group type: OTHER
Intervention: Giomer
Description: Giomers are dental materials that are hybrid of compomers and glass ionomers, and are used to restore dental caries.

Intervention type: DEVICE
Group type: OTHER
Intervention: Giomer
Description: Giomers are dental materials that are hybrid of compomers and glass ionomers, and are used to restore dental caries.
Study: NCT06754553

Intervention type: BEHAVIORAL
Intervention: Assessment of severity of ICD (impulse control disorders)
Description: Questionnaire for impulsive-compulsive disorders in Parkinson's disease rating scale (QUIP-RS) administered at day 0, day 28 (Week 4) and day 56 (Week 8)

Intervention type: BEHAVIORAL
Intervention: Assessment of severity of ICD (impulse control disorders)
Description: Questionnaire for impulsive-compulsive disorders in Parkinson's disease rating scale (QUIP-RS) administered at day 0, day 28 (Week 4) and day 56 (Week 8)
Study: NCT06620172

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT-guided Radiofrequency Thermocoagulation (RFT)
Description: Participants in this group will undergo CT-guided trigeminal ganglion radiofrequency thermocoagulation (RFT). The procedure involves real-time CT imaging to guide the placement of the needle and monitor the process.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopy-guided Radiofrequency Thermocoagulation (RFT)
Description: Participants in this group will undergo fluoroscopy-guided trigeminal ganglion radiofrequency thermocoagulation (RFT). The procedure utilizes fluoroscopic imaging for needle placement and monitoring.
Study: NCT06754553

Intervention type: BEHAVIORAL
Intervention: Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors
Description: Hyper- and hypodopaminergic behaviors (Ardouin's scale); Movement disorders society sponsored unified Parkinson's disease rating scale (MDS-UPDR), and daytime and night time sleep by scale for outcomes in Parkinson's disease SLEEP (SCOPA-SLEEP, ISI, PDSS-2) administered at day 0, day 28 (Week 4) and day 56 (Week 8)

Intervention type: BEHAVIORAL
Intervention: Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors
Description: Hyper- and hypodopaminergic behaviors (Ardouin's scale); Movement disorders society sponsored unified Parkinson's disease rating scale (MDS-UPDR), and daytime and night time sleep by scale for outcomes in Parkinson's disease SLEEP (SCOPA-SLEEP, ISI, PDSS-2) administered at day 0, day 28 (Week 4) and day 56 (Week 8)

Intervention type: BEHAVIORAL
Intervention: Assessment of quality of life
Description: Parkinson's Disease questionnaire (PDQ-39) administered at day 0, day 28 (Week 4) and day 56 (Week 8)

Intervention type: BEHAVIORAL
Intervention: Assessment of quality of life
Description: Parkinson's Disease questionnaire (PDQ-39) administered at day 0, day 28 (Week 4) and day 56 (Week 8)

Intervention type: BEHAVIORAL
Intervention: Assessment of depression
Description: Montgomery-Åsberg Depression Rating Scale (MADRS) administered at day 0 and day 56 (week 8)

Intervention type: BEHAVIORAL
Intervention: Assessment of depression
Description: Montgomery-Åsberg Depression Rating Scale (MADRS) administered at day 0 and day 56 (week 8)

Intervention type: BEHAVIORAL
Intervention: Assessment of cognition
Description: Cognitive state of patients by Montreal Cognitive Assessment (MOCA) assessed at day 0

Intervention type: BEHAVIORAL
Intervention: Assessment of cognition
Description: Cognitive state of patients by Montreal Cognitive Assessment (MOCA) assessed at day 0

Intervention type: BEHAVIORAL
Intervention: Assessment of severity of Parkinson Disease
Description: Clinical Global Impression Severity scale (CGIS) administered at day 0 , day 7, day 14, day 28, day 42 and day 56 (week 8) and day 112 (Week 16)

Intervention type: BEHAVIORAL
Intervention: Assessment of severity of Parkinson Disease
Description: Clinical Global Impression Severity scale (CGIS) administered at day 0 , day 7, day 14, day 28, day 42 and day 56 (week 8) and day 112 (Week 16)

Intervention type: PROCEDURE
Intervention: Cardiac monitoring
Description: Electrocardiogram realized at day 0, 28 and 56.

Intervention type: PROCEDURE
Intervention: Cardiac monitoring
Description: Electrocardiogram realized at day 0, 28 and 56.
Study: NCT06753331

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: DSP-1083 implantation
Description: DSP-1083 subjects will receive 2.7M viable cells per hemisphere; 5.4M total cell dose as implants.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham surgery treatment
Description: Sham surgery subjects will undergo a partial thickness burr hole surgical procedure on each side of the skull with no DSP-1083 administration.
Study: NCT06754761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] AZD6738
Description: radiolabeled AZD6738 / ceralasertib
Study: NCT05072249

Intervention type: DRUG
Intervention: Naloxone
Description: Take Home Naloxone for reversing opioid overdose
Study: NCT06754761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738 / ceralasertib
Description: Ceralasertib (AZD6738) is a potent, selective inhibitor of the serine/threonine-specific protein kinase ATR
Study: NCT06753032

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Positive Lens-Induced Defocus Using Spectacle Lenses (+2.00 D) for Myopic Participants
Description: Intervention Description: This group will be exposed to positive defocus induced by +2.00 D spectacle lenses. The lenses are designed to create optical blur to evaluate the effects on contrast sensitivity and visual fatigue. Measurements will be conducted at baseline, 2 weeks, and 4 weeks after exposure to assess changes in visual function.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Negative Lens-Induced Defocus Using Spectacle Lenses (-2.00 D) for Myopic Participants
Description: Intervention Description: This group will be exposed to negative defocus induced by -2.00 D spectacle lenses. The induced defocus will allow for the evaluation of its impact on contrast sensitivity and visual fatigue. Assessments will be carried out at baseline, 2 weeks, and 4 weeks.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Positive Lens-Induced Defocus Using Spectacle Lenses (+2.00 D) for Non-Myopic Participants
Description: ntervention Description: This group will undergo positive defocus using +2.00 D spectacle lenses. The intervention aims to examine the effect of induced defocus on contrast sensitivity and visual fatigue in non-myopic participants. Data will be collected at baseline, 2 weeks, and 4 weeks.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Negative Lens-Induced Defocus Using Spectacle Lenses (-2.00 D) for Non-Myopic Participants
Description: Intervention Description: This group will experience negative defocus induced by -2.00 D spectacle lenses. The purpose is to evaluate how negative lens-induced defocus affects contrast sensitivity and visual fatigue in non-myopic participants. Measurements will be taken at baseline, 2 weeks, and 4 weeks.
Study: NCT06755268

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: listening to nature sounds (the sound of birds, water flowing in a river, wind or walking in the forest) based music
Description: Listening to nature sounds (the sound of birds, water flowing in a river, wind or walking in the forest) based music during the angiography procedure.
Study: NCT06753084

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alloderm
Description: the study is done to patient who lacks of keratinized mucosa width by apically positioned flap and using of FGG as gold standard and Mucoderm as compartive group

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alloderm
Description: the study is done to patient who lacks of keratinized mucosa width by apically positioned flap and using of FGG as gold standard and Mucoderm as compartive group
Study: NCT06373432

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fingerstick
Description: Fingerstick to check glucose value during labor.
Study: NCT05445414

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SteWARdS Antibiotic Defense app
Description: The SteWARdS Antibiotic Defense app is an evidence-based serious game app developed by the study team. The app uses gamification theories to increase user engagement and to deliver bite-sized information to participants. For example, players will learn about the uses of antibiotics through the messages delivered through the game and the cost of tackling antibiotic-resistant infections through purchasing an expensive antibiotic with the virtual currency earned from the games.